11 completed, 4 unknown, 1 active not recruiting, 1 enrolling by invitation. 3 Phase 4, 2 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Enrolling by invitation 1, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Severe Eosinophilic Asthma: new trials by email Literature Review of Severe Eosinophilic Asthma trials Research Report on Severe Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma Depemokimab - Allergic Bronchopulmonary Aspergillosis, ABPA | Not applicable | Not yet recruiting | Qianfoshan Hospital | 10 | 2026-11-01 | 2026-09-24 |
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy benralizumab - Severe Eosinophilic Asthma | Recruiting | AstraZeneca | 335 | 2025-12-20 | 2026-09-18 | |
| Clock Proteins as Prognostic Markers Severe Eosinophilic Asthma | Terminated | Medical University of Graz | 50 | 2024-05-01 | 2025-10-03 | |
| STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 504 | 2024-02-28 | 2026-09-03 |
| Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma Mepolizumab 100 MG - Chronic Rhinosinusitis With Nasal Polyps, Severe Eosinophilic Asthma | Active not recruiting | National and Kapodistrian University of Athens | 40 | 2023-09-01 | 2026-04-17 | |
| A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab. Cohort - Severe Eosinophilic Asthma | Completed | AstraZeneca | 152 | 2022-06-29 | 2026-04-15 | |
| Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST) Severe Eosinophilic Asthma | Completed | AstraZeneca | 3 | 2022-05-16 | 2024-10-21 | |
| Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma Mepolizumab - Severe Eosinophilic Asthma | Completed | Istituti Clinici Scientifici Maugeri SpA | 15 | 2021-11-25 | 2026-10-15 | |
| RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps. FASENRA(benralizumab) - Severe Eosinophilic Asthma, Nasal Polyps | Completed | AstraZeneca | 273 | 2021-11-23 | 2023-04-19 | |
| Severe Asthma, MepolizumaB and Affect: SAMBA Study no study intervention. Patients receive standard clinical care - Severe Eosinophilic Asthma, Psychological Distress | Completed | University Hospital Southampton NHS Foundation Trust | 120 | 2021-09-09 | 2026-07-13 | |
| Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma Dermatophagoides pteronyssinus allergen, Blood sampling, Bronchial challenge with allergen - Allergic Asthma, Severe Eosinophilic Asthma | Not applicable | Unknown | Lithuanian University of Health Sciences | 80 | 2020-10-01 | 2020-09-09 |
| A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Symbicort®, Fasenra®, Ventolin® - Asthma, Severe Eosinophilic Asthma | Phase 4 | Completed | AstraZeneca | 170 | 2020-07-27 | 2025-01-09 |
| Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain Severe Eosinophilic Asthma | Completed | AstraZeneca | 28 | 2020-01-13 | 2021-06-29 | |
| Real World Study With Benralizumab in Severe Asthma in Switzerland Severe Eosinophilic Asthma | Completed | AstraZeneca | 79 | 2019-01-21 | 2024-02-29 | |
| Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab. Survey Administration - Severe Eosinophilic Asthma | Completed | AstraZeneca | 170 | 2018-11-12 | 2024-07-01 | |
| Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma Benralizumab - Severe Eosinophilic Asthma | Phase 4 | Unknown | University of Rostock | 20 | 2018-09-01 | 2018-08-29 |
| A Study on the Effect of Mepolizumab Therapy on Daily Physical Activity of Patients With Severe Eosinophilic Asthma Mepolizumab 100 MG Injection [Nucala] - Severe Eosinophilic Asthma | Unknown | Sotiria General Hospital | 50 | 2017-12-11 | 2018-11-13 | |
| Mepolizumab: Real World Evidence Study for the Treatment of Severe Eosinophilic Asthma in Greece Severe Eosinophilic Asthma | Unknown | Attikon Hospital | 150 | 2017-01-01 | 2019-09-12 | |
| Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma OC000459, Placebo - Severe Eosinophilic Asthma | Phase 2 | Completed | Chiesi Farmaceutici S.p.A. | 40 | 2016-09-01 | 2019-08-29 |
Pulmonary Eosinophilia (20) · Asthma (5) · Nasal Polyps (2) · Anxiety Disorders (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Depression (1) · Inflammation (1) · Mental Disorders (1) · Stress, Psychological (1)
Eosinophilia (20) · Hematologic Diseases (20) · Hemic and Lymphatic Diseases (20) · Hypereosinophilic Syndrome (20) · Leukocyte Disorders (20) · Lung Diseases (20) · Respiratory Tract Diseases (20) · Hypersensitivity (6) · Hypersensitivity, Immediate (6) · Immune System Diseases (6) · Respiratory Hypersensitivity (6) · Bronchial Diseases (5) · Lung Diseases, Obstructive (5) · Pathological Conditions, Signs and Symptoms (3) · Nose Diseases (2)
benralizumab (6) · mepolizumab (3) · (5-fluoro-2-methyl-3-quinolin-2-ylmethylindo-1-yl)acetic acid (1) · Albuterol (1) · Allergens (1) · Antigens, Dermatophagoides (1) · Blood Specimen Collection (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Cohort Studies (1) · Injections (1)
AstraZeneca (9) · Attikon Hospital (1) · Chiesi Farmaceutici S.p.A. (1) · Endeavor Health (1) · Istituti Clinici Scientifici Maugeri SpA (1) · Lithuanian University of Health Sciences (1) · Medical University of Graz (1) · National and Kapodistrian University of Athens (1) · Qianfoshan Hospital (1) · Sotiria General Hospital (1) · University Hospital Southampton NHS Foundation Trust (1) · University of Rostock (1)
Italy (4) · Germany (3) · Greece (3) · United Kingdom (3) · China (2) · France (2) · Spain (2) · United States (2) · Austria (1) · Canada (1) · Japan (1) · Lithuania (1) · Russia (1) · Switzerland (1)
Dr. David Jackson (1) · Eleni Loutrari, PhD (1) · Erika Penz, MD (1) · Giselle Mosnaim, MD, MS (1) · HuaHao Shen, Professor (1) · Ian Pavord, Professor (1) · Marek Lommatzsch, MD (1) · Marios Panagiotou, MD (1) · Min Zhang, Professor (1) · Paraskevi Katsaounou, MD, PhD, Msc (1) · Thomas Rothe, Dr. med. (1)
PMID 32762056, PMID 33369570, PMID 38071986, PMID 38595692, PMID 39741370, PMID 41304949
2015 (1), 2019 (1)